Startups
Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.
Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact.
Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact.
Overview
Location
United States, California, Sunnyvale
Employees
1-10
Phone
+1 415-688-4484
Total raised
$8M
Founded date
2008
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Nov 17, 2014 | Funding round | $3M |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 27, 2015 | Amarantus Bio Raises $5M | |
| Sep 30, 2013 | NeuroTrack’s computer test for Alzheimer’s wins over Founders Fund, Social+Capital Partnership | The test monitors the eyes of seniors as they view a series of image pairs on a computer screen. It tracks how eyes respond to novel and repeat images shown on the screen — healthy patients tend to gravitate more toward novel images, wherea... |
| NeuroTrack’s computer test for Alzheimer’s wins over Founders Fund, Social+Capital Partnership | What if a simple computer test administered in a doctor’s office could foretell which seniors would develop Alzheimer’s disease down the road? Startup NeuroTrack is working toward that, and now a few notable investors have joined in. NeuroT... |
Reviews 0
FAQ about Amarantus BioScience
When was Amarantus BioScience founded?
Amarantus BioScience was founded in 2008.
How much funding has Amarantus BioScience raised?
Amarantus BioScience has raised $8M in total across 2 funding rounds.
What funding rounds has Amarantus BioScience raised?
Parsers VC lists 2 funding rounds of Amarantus BioScience, among them a funding round of $3M on Nov 17, 2014.
What has the press written about Amarantus BioScience?
Parsers VC has collected 4 articles mentioning Amarantus BioScience, among them “Amarantus Bio Raises $5M” (Apr 27, 2015) and “NeuroTrack’s computer test for Alzheimer’s wins over Founders Fund, Social+Capital Partnership” (Sep 30, 2013).
Is Amarantus BioScience still active?
Amarantus BioScience is probably closed: its latest activity on Parsers VC dates from Apr 27, 2022.